Out­rac­ing 2 gi­ant ri­vals, J&J touts promis­ing PhI­II In­vokana da­ta as a game-chang­er for kid­ney dis­ease risks

In a race to ex­pand mar­ket share against two top ri­vals in the di­a­betes field, J&J just scored one in the win col­umn. And they’ll play it for all it’s worth in an at­tempt to re­vive flag­ging sales.

Re­searchers for the phar­ma gi­ant spelled out a sig­nif­i­cant ad­van­tage for di­a­bet­ics tak­ing their SGLT2 stan­dard bear­er In­vokana. In a Phase III study, the drug scored a 30% re­duc­tion in the risk of a com­pos­ite of ail­ments that many pa­tients face: a pro­gres­sion to the dou­bling of serum cre­a­ti­nine, end-stage kid­ney dis­ease and re­nal or car­dio­vas­cu­lar death. Just look­ing at ES­KD — a ma­jor fear among tens of mil­lions of di­a­bet­ics, 40% of whom will go on to de­vel­op kid­ney dis­ease — there was a 32% re­duc­tion in risk.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.